CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB

Stefanie Lerche, PhD,1,2 Simon Sjödin, PhD,3,4 Ann Brinkmalm, MD,3,4 Isabel Wurster, MD,1,2 Benjamin Roeben, MD,1,2 Milan Zimmermann, MD,1,2 Ann-Kathrin Hauser,1,2 Inga Liepelt-Scarfone, PhD,1,2 Katharina Waniek, PhD,5 Ingolf Lachmann, PhD,5 Thomas Gasser, MD,1,2 Henrik Zetterberg, MD,3,4,6,7 and Kathrin Brockmann, MD1,2*

1 Center of Neurology, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tübingen, Germany
2 German Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany
3 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
4 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
5 Roboscreen GmbH, Leipzig, Germany
6 Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
7 UK Dementia Research Institute at UCL, London, United Kingdom

ABSTRACT: Background: Molecular pathways associated with α-synuclein proteostasis have been detected in genetic studies and in cell models and include autophagy, ubiquitin-proteasome system, mitochondrial homeostasis, and synaptic plasticity. However, we lack biomarkers that are representative for these pathways in human biofluids.

Objective: The objective of this study was to evaluate CSF protein profiles of pathways related to α-synuclein proteostasis.

Methods: We assessed CSF protein profiles associated with neurotransmitter secretion, synaptic plasticity, and autophagy in 2 monocentric cohorts with α-synucleinopathy (385 PD patients and 67 DLB patients). We included 80 PD patients and 17 DLB patients with variants in the glucocerebrosidase gene to serve as proxy for accelerated α-synuclein pathology with pronounced clinical trajectories.

Results: (1) Proteins associated with neurotransmitter secretion, synaptic plasticity, and endolysosomal autophagy were lower in PD and DLB patients compared with healthy controls. (2) These patterns were more pronounced in DLB than in PD patients, accentuated by GBA variant status in both entities. (3) CSF levels of these proteins were positively associated with CSF levels of total α-synuclein, with lower levels of proteostasis proteins related to lower levels of total α-synuclein. (4) These findings could be confirmed longitudinally. PD patients with low CSF profiles of proteostasis proteins showed lower CSF levels of α-synuclein longitudinally compared with PD patients with a normal proteostasis profile.

Conclusion: CSF proteins associated with neurotransmitter secretion, synaptic plasticity, and endolysosomal autophagy might serve as biomarkers related to α-synuclein proteostasis in PD and DLB. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Key Words: lysosome; secretion; synaptic plasticity; CSF; PD; GBA
In the large majority of patients with α-synucleinopathies such as Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), the common pathologic feature is the aggregation of abnormal conformations of the protein α-synuclein. 1 Subsequently, several molecular pathways associated with α-synuclein proteostasis have been detected in genetic studies as well as in cell and animal models. These include impairment in autophagy with, for example, endolysosomal dysfunction, ubiquitin-proteasome system, mitochondrial homeostasis, and synaptic plasticity. 2 Despite this clear evidence for pathways involved, we lack validated biomarkers that are clearly disease- and/or pathway-specific in human biofluids. A recent study performed a targeted approach and explored cerebrospinal fluid (CSF) peptide/protein profiles associated with autophagic endolysosomal and ubiquitin-proteasome function using solid-phase extraction combined with parallel reaction monitoring mass spectrometry in 3 cohorts of PD patients, Alzheimer’s disease (AD) patients, and healthy controls. Interestingly, CSF protein levels of lysosomal-associated membrane glycoprotein 1 and 2 (LAMP1 and LAMP2), cathepsin F (CTSF), ganglioside GM2 activator (GM2A), AP-2-complex subunit beta (AP2B1), and ubiquitin were lower in PD patients than in AD patients, prodromal AD patients, and healthy controls. 3 With advancing techniques, a recent unbiased quantitative proteomics approach using liquid chromatography–tandem mass spectrometry in data-independent acquisition mode reported decreased CSF levels of proteins associated with neurotransmitter secretion (granin family) as well as with adherens junctions in sporadic PD patients compared with healthy controls. 4 Specifically, CSF protein levels of neurosecretory protein VGF, secretogranin 2 (SCG2), secretogranin 3, and secretogranin 5, chromogranin-A (CHGA) and chromogranin-B, and cadherins were lower in PD. Following this line of evidence, we aimed to evaluate CSF protein profiles associated with pathways of α-synuclein proteostasis in 2 large monocentric cohorts with α-synucleinopathy including a total of 385 PD patients and 67 DLB patients compared with healthy controls. As impaired lysosomal chaperone-mediated autophagy represents a key mechanism in PD, we specifically included PD patients (80 of 385) and DLB patients (17 of 67) with variants in the glucocerebrosidase (GBA) gene. Given the accelerated α-synuclein pathology and pronounced clinical trajectories in DLB compared with PD and in patients with GBA variants compared with the wild-type condition, our primary hypothesis was that profiles in those patient groups would be more distinct.

Participants and Methods

Participants

Between 2005 and 2018, PD patients and DLB patients were recruited from the outpatient clinic and/or ward for Parkinson’s disease at the University Hospital of Tuebingen for scientific lumbar puncture. In total, CSF samples from 305 sporadic PD patients without the GBA variant (PDGBA-wildtype), 80 PD patients with the GBA variant (PDGBA), 50 DLB patients without the GBA variant (DLGBA-wildtype), and 17 DLB patients with the GBA variant (DLGBA) were available. Clinical data and CSF levels of total α-synuclein of 210 PD patients with a median follow-up time of 4 years were available for longitudinal analysis. Spouses of patients and volunteers were clinically assessed to have no neurodegenerative disease and served as control participants (HCs, n = 31).

Genetic Analysis

Genetic screening of all exons of the GBA gene was performed by Sanger sequencing.

We performed GBA subgroup classification for variant severity according to established variant risks reported for PD. Of note, some variants that have been reported as nonrelevant for Gaucher disease have been proven to increase the risk for PD and therefore have been included in our analysis, for example, p.E326K and p.T369M. GBA variants were categorized as: GBA_low_risk, E326K, T297S, T369M; GBA_mild, R120Q, R359X, W184R.

Clinical Investigations

All participants were examined by a neurologist who specialized in movement disorders. Diagnosis of PD was defined according to the UK Brain Bank Society criteria. 5 Diagnosis of DLB was made according to the revised consensus criteria for DLB developed by the third report of the DLB consortium. 6 PD and DLB patients were assessed in the dopaminergic ON state, levodopa-equivalent daily dose (LEDD) was calculated. We assessed severity of motor symptoms using part III of the Unified Parkinson’s disease Rating Scale (UPDRS-III), from 2006 to 2008 the old version and from 2009 on the MDS-UPDRS. 7 Disease stage was categorized by the modified Hoehn and Yahr Scale (H&Y). 8 Cognitive function was tested using the Montreal Cognitive Assessment (MoCA). 9 and/or the Mini-Mental Status Examination (MMSE). 10 Because the MoCA was available only from 2009 on, all previously obtained MMSE scores were converted to MoCA-equivalent scores. 11 Mood disturbances were assessed using Beck’s Depression Inventory II (BDI-II).

Collection of CSF

Spinal tap was performed between 9:00 AM and 1:00 PM. Samples were directly taken from the bedside and centrifuged within 60 minutes and frozen at −80°C.
within 90 minutes. Samples with abnormal routine CSF diagnostics (white blood cell count > 6 cells/μL, immunoglobulin subtype G index > 0.7, erythrocytes > 1/μL) were excluded.

**CSF Measurement of Total α-Synuclein, Aβ1-42, Total-Tau, Phospho-Tau**

CSF levels of total α-synuclein were assessed using hSYN total enzyme-linked immunosorbent assay (ELISA) from AJ Roboscreen (Germany). The assay uses a monoclonal capture antibody recognizing amino acids 119–126 and a detection antibody to the C-terminus of α-synuclein. Intra-assay imprecision was 4.4%, and interassay imprecision was below 10%.

CSF levels of Aβ1-42, total-tau (t-tau), and phospho-tau (p-tau; phosphorylated at T181) were measured using commercially available ELISA kits (INNOTEST; Fujirebio GmbH, Germany). The intra-assay coefficients of variation for each CSF parameter were below 15%. Concomitant AD CSF profile was defined if Aβ1-42 < 650 pg/mL and either h-tau > 450 pg/mL or p-tau > 61 pg/mL.

**CSF Measurements of Proteins Related to α-Synuclein Proteostasis**

1. **Neurotransmitter secretion**: CHGA, SCG2, VGF.
2. **Synapse plasticity**: NPTX1.
3. **Autophagy, including endocytosis, lysosomal function, ubiquitin-proteasome system**: AP2B1, CTSF, GM2A, LAMP2, ubiquitin.

**Sample Preparation**

Measurement of protein concentrations was performed as previously described. Briefly, 50 μL of CSF was mixed with 50 μL of an internal standard mixture containing stable isotope-labeled peptides (JPT Peptide Technologies GmbH, Germany; Thermo Fisher Scientific Inc., Waltham, MA), 13C-labeled ubiquitin (Silantes, GmbH, Germany), and bovine serum albumin (Sigma-Aldrich Co., St. Louis, MO) diluted in 50 mM NH4HCO3. Reduction and alkylation were performed by the addition of 50 μL of 15 mM 1,4-dithiothreitol in 50 mM NH4HCO3, shaking for 30 minutes at 60°C, cooling down at room temperature for 30 minutes, and the addition of 25 μL of 70 mM iodoacetamide in 50 mM NH4HCO3, followed by shaking at room temperature in the dark for 30 minutes. Samples were digested by the addition of 25 μL of 0.08 μg/μL sequencing-grade modified trypsin (Promega Co., Madison, WI) diluted in 50 mM NH4HCO3 and incubated at 37°C shaking for 18 hours. Digestion was ended by the addition of 25 μL of 10% trifluoroacetic acid. Solid-phase extraction was performed using Oasis HLB 96-well µElution Plates (2 mg sorbent and 30-μm particle size; Waters Co., Milford, MA) by conditioning (2 × 300 μL methanol), equilibration (2 × 300 μL H2O), loading of samples, washing (2 × 300 μL H2O), and elution (2 × 100 μL methanol). Samples were dried by vacuum centrifugation and stored at −80°C.

**Parallel Reaction Monitoring Mass Spectrometry**

Samples were dissolved by the addition of 50 μL of 50 mM NH4HCO3 and shaker at room temperature for 1 hour. A total of 40 μL of sample was injected and separated using a Dionex UltiMate 3000 standard-LC system (Thermo Fisher Scientific Inc., Waltham, MA) and a Kinetek EVO C18 column (length, 150 mm; inner diameter, 2.1 mm; particle size, 1.7 μm; Phenomenex Inc., Torrance, CA) with a SecurityGuard ULTRA cartridge prefilter (Phenomenex Inc.). With a 60-minute method, with solvents A (0.1% formic acid in H2O [v/v]) and B (84% acetonitrile and 0.1% formic acid in H2O [v/v]), using a flow rate of 300 μL/min, the gradient went from 3% to 5% B over 1 minute, followed by 5% to 26% B over 48 minutes. The column temperature was set to 50°C. Separation by high-performance liquid chromatography was performed in online mode coupled to a Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific Inc.). Using a HESI-II ionization probe (Thermo Fisher Scientific Inc.), electrospray ionization was performed in positive ion mode with the following settings: spray voltage, +4.1 kV; heater temperature, 400°C; capillary transfer tube temperature, 380°C; sheath gas flow rate, 25; auxiliary gas flow rate, 10; and S-Lens RF level, 60. Acquisition of data was performed using single microscans in parallel reaction monitoring (PRM) mode with an isolation window of m/z 2 centered on the second isotope of the precursor ion. The resolution setting was 70 k, with an AGC target of 1 × 106 and a 256-millisecond injection time. Fragmentation was performed using higher-energy collision-induced dissociation.

**Data Extraction**

Skyline v.19.1 was used to calculate and export fragment ion peak areas and to monitor fragment ion traces and ratios. The ratio between tryptic peptide and isotope-labeled peptide peak area was used for quantification.

**Statistics**

Statistical analysis was performed using IBM SPSS 26.0 software. Dichotomous data were analyzed using the Fisher’s exact test or the chi-square test. Homogeneity of variance of the variables was evaluated using Levene’s test, which showed P > 0.05. Intergroup comparisons of demographics, clinical markers, and CSF protein levels were calculated using analysis of variance/analysis of covariance (ANOVA/ANCOVA) including sex, age, and disease duration as covariates as
appropriate. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were calculated to evaluate discriminant capabilities of CSF proteins between patient groups and controls. Pearson’s correlation was used to evaluate associations between CSF protein levels.

In PD patients, for each CSF protein associated with pathways related to α-synuclein proteostasis, we assessed the optimal cutoff for pathological levels by calculating Youden’s index (Table S3). Values greater than the optimal diagnostic cutoff were considered normal (PD\textsubscript{normal_proteostasis_profile}), whereas those below indicated pathologically reduced protein (PD\textsubscript{pathological_proteostasis_profile}).

Longitudinal analysis of CSF levels of total α-synuclein and clinical trajectories between PD\textsubscript{pathological_proteostasis_profile} versus PD\textsubscript{normal_proteostasis_profile} was done using a linear mixed model with the fixed factors group (PD\textsubscript{pathological_proteostasis_profile}, PD\textsubscript{normal_proteostasis_profile}) and time (time of follow-up in years), their interaction, and the random variable subject, modeled by random intercepts. The addition of random slopes did not improve model fit. CSF levels of total α-synuclein, MoCA, UPDRS-III, H&Y stage, BDI-II were defined as dependent variables. We analyzed the fixed effect of group, time, and the interaction of group and time on the dependent variable.

**Standard Protocol Approval, Registrations, and Patient Consents**

The study was approved by the Ethics Committee of the University of Tuebingen (26/2007BO1, 404/2010BO1, 199/2011BO1, 702/2013BO1). All participants gave written informed consent.

**Results**

**Demographics and Clinical Characteristics**

PD\textsubscript{GBA} was younger in mean age (64 vs 66 years; \(P = 0.034\)) and in mean age at onset (56 vs 60 years; \(P = 0.002\)) and had a longer mean disease duration (8 vs 7 years; \(P = 0.018\)) compared with PD\textsubscript{GBA_wildtype}. UPDRS-III, H&Y stage, MoCA, BDI-II score, and LEDD were not significantly different between PD\textsubscript{GBA} and PD\textsubscript{GBA_wildtype}. Demographics and clinical variables did not differ significantly between DLB\textsubscript{GBA_wildtype} and DLB\textsubscript{GBA}. All PD and DLB groups were older than healthy control participants (\(P \leq 0.001\); Table 1).

**CSF Total α-Synuclein, Aβ_{1-42}, Total-Tau, and Phospho-Tau**

PD\textsubscript{GBA} showed lower mean CSF α-synuclein compared with PD\textsubscript{GBA_wildtype} (549 vs 623 pg/mL; \(P = 0.022\)). The same pattern was seen in DLB\textsubscript{GBA} compared with DLB\textsubscript{GBA_wildtype} (457 vs 518 pg/mL; \(P = 0.032\)). Mean CSF levels of Aβ_{1-42}, total-tau, and phospho-tau did not differ between PD and DLB patients with GBA variants compared with those without GBA variant. DLB patients more often presented with CSF profiles indicative of AD pathology compared with PD patients and with HCs (21%, 7%, 3%; \(P \leq 0.001\)). In DLB patients, those with DLB\textsubscript{GBA_wildtype} more often showed CSF AD profiles compared with DLB\textsubscript{GBA} and HCs (26%, 6%, 3%; \(P = 0.011\)). No differences in CSF AD profiles were found when comparing PD patients with versus those without the GBA variant (8%, 5%; \(P = 0.447\)).

**CSF Proteins Related to α-Synuclein Proteostasis**

**Neurotransmitter Secretion**

CSF levels of CHGA, SCG2, and VGF were lower in PD\textsubscript{GBA_wildtype}, PD\textsubscript{GBA}, DLB\textsubscript{GBA_wildtype} and DLB\textsubscript{GBA} compared with healthy controls (\(P \leq 0.001\); Table 1).

Within the group of PD patients, PD\textsubscript{GBA_severe} patients had lower CSF levels of SCG2 compared with PD\textsubscript{GBA_wildtype} patients (0.80 vs 1.02) and lower CSF levels of VGF compared with PD\textsubscript{GBA_low_risk} and PD\textsubscript{GBA_wildtype} patients (0.70 vs 1.05 vs 1.04, respectively; \(P < 0.05\); Table S1).

Within the group of DLB patients, DLB\textsubscript{GBA_mild_severe} had lower CSF levels of CHGA and SCG2 compared with DLB\textsubscript{GBA_wildtype} (CHGA, 0.38 vs 0.83, respectively; SCG2, 0.50 vs 0.83, respectively; \(P < 0.05\); Table S2).

**Synaptic Plasticity**

CSF levels of NPTX1 showed a trend toward being lower in PD\textsubscript{GBA} (\(P = 0.087\)) and were significantly lower in DLB\textsubscript{GBA_wildtype} and DLB\textsubscript{GBA} compared with healthy controls (\(P \leq 0.001\); Table 1). Stratification according to GBA variant severity revealed no significant differences between the PD and DLB groups (Tables S1 and S2).

**Autophagy Including Endocytosis, Lysosomal Function, Ubiquitin-Proteasome System**

CSF levels of AP2B1 were lower in PD\textsubscript{GBA_wildtype} (1.01), PD\textsubscript{GBA} (0.94), DLB\textsubscript{GBA_wildtype} (0.96), and DLB\textsubscript{GBA} (0.84) compared with healthy controls (1.13); \(P \leq 0.01\). CSF levels of GM2A and LAMP2 were lower in DLB\textsubscript{GBA_wildtype} (0.98 and 1.04) and DLB\textsubscript{GBA} (0.87 and 0.87) compared with healthy controls (1.07 and 1.14); \(P < 0.05\) and \(P < 0.01\), respectively. CSF levels of ubiquitin were lower in PD\textsubscript{GBA_wildtype} (1.00) and PD\textsubscript{GBA} (0.94) compared with healthy controls (1.14); \(P < 0.001\). CSF levels of CTSF showed no significant differences between groups.
TABLE 1 CSF levels of pathway-associated proteins in PD patients, DLB patients, and controls

<table>
<thead>
<tr>
<th></th>
<th>Controls, n = 31</th>
<th>PDGBA_wildtype, n = 305</th>
<th>PDGBA, n = 80</th>
<th>P overall</th>
<th>DLBGABA_wildtype, n = 50</th>
<th>DLBGABA, n = 17</th>
<th>P overall</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex (male), n (%)</strong></td>
<td>16 (52)</td>
<td>200 (65)</td>
<td>55 (69)</td>
<td>0.569</td>
<td>34 (68)</td>
<td>14 (82)</td>
<td>0.257</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>57 ± 13</td>
<td>66 ± 9c</td>
<td>64 ± 10f</td>
<td>0.034</td>
<td>73 ± 6</td>
<td>71 ± 5</td>
<td>0.131</td>
</tr>
<tr>
<td><strong>Age at onset (years)</strong></td>
<td>60 ± 10</td>
<td>56 ± 10</td>
<td>56 ± 10</td>
<td>0.002</td>
<td>70 ± 7</td>
<td>67 ± 6</td>
<td>0.199</td>
</tr>
<tr>
<td><strong>Disease duration (years)</strong></td>
<td>7 ± 4</td>
<td>8 ± 5</td>
<td>7 ± 4</td>
<td>0.018</td>
<td>3 ± 2</td>
<td>3 ± 1</td>
<td>0.888</td>
</tr>
<tr>
<td><strong>Hoehn &amp; Yahr</strong></td>
<td>2.1 ± 0.6</td>
<td>2.3 ± 0.7</td>
<td>2.02</td>
<td>0.202</td>
<td>2.5 ± 0.6</td>
<td>2.3 ± 0.4</td>
<td>0.354</td>
</tr>
<tr>
<td><strong>UPDRS-III</strong></td>
<td>26 ± 12</td>
<td>28 ± 12</td>
<td>28 ± 12</td>
<td>0.303</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td><strong>MoCA</strong></td>
<td>25 ± 4</td>
<td>24 ± 5</td>
<td>25 ± 4</td>
<td>0.161</td>
<td>14 ± 4</td>
<td>15 ± 5</td>
<td>0.761</td>
</tr>
<tr>
<td><strong>BDI-II</strong></td>
<td>6 ± 5</td>
<td>9 ± 7</td>
<td>7 ± 10</td>
<td>0.188</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td><strong>LEDD</strong></td>
<td>553 ± 379</td>
<td>609 ± 385</td>
<td>247</td>
<td>0.247</td>
<td>306 ± 265</td>
<td>272 ± 244</td>
<td>0.646</td>
</tr>
<tr>
<td><strong>Chromogranin A</strong></td>
<td>1.29 ± 0.65</td>
<td>1.04 ± 0.66b</td>
<td>0.92 ± 0.58c</td>
<td>0.005</td>
<td>0.83 ± 0.59c</td>
<td>0.57 ± 0.21c</td>
<td>≤0.001</td>
</tr>
<tr>
<td><strong>Secretogranin 2</strong></td>
<td>1.36 ± 0.55</td>
<td>1.02 ± 0.46c</td>
<td>0.93 ± 0.46c</td>
<td>≤0.001</td>
<td>0.83 ± 0.42c</td>
<td>0.66 ± 0.24c</td>
<td>≤0.001</td>
</tr>
<tr>
<td><strong>Neurosecretory protein VGF</strong></td>
<td>1.45 ± 0.69</td>
<td>1.04 ± 0.60f</td>
<td>0.93 ± 0.63c</td>
<td>≤0.001</td>
<td>0.70 ± 0.48c</td>
<td>0.50 ± 0.24c</td>
<td>≤0.001</td>
</tr>
<tr>
<td><strong>Neuronal pentraxin 1</strong></td>
<td>1.15 ± 0.37</td>
<td>1.02 ± 0.41</td>
<td>0.96 ± 0.39</td>
<td>0.087</td>
<td>0.85 ± 0.46c</td>
<td>0.73 ± 0.24c</td>
<td>≤0.001</td>
</tr>
<tr>
<td><strong>AP2 complex subunit beta</strong></td>
<td>1.13 ± 0.33</td>
<td>1.01 ± 0.40b</td>
<td>0.94 ± 0.35c</td>
<td>0.006</td>
<td>0.96 ± 0.49b</td>
<td>0.84 ± 0.29c</td>
<td>0.004</td>
</tr>
<tr>
<td><strong>Cathepsin F</strong></td>
<td>1.02 ± 0.20</td>
<td>1.01 ± 0.27</td>
<td>0.97 ± 0.23</td>
<td>0.400</td>
<td>0.99 ± 0.31</td>
<td>0.99 ± 0.21</td>
<td>0.098</td>
</tr>
<tr>
<td><strong>Ganglioside GM2 activator</strong></td>
<td>1.07 ± 0.28</td>
<td>1.01 ± 0.35</td>
<td>0.98 ± 0.35</td>
<td>0.072</td>
<td>0.98 ± 0.48c</td>
<td>0.87 ± 0.24b</td>
<td>0.020</td>
</tr>
<tr>
<td><strong>LAMP2 area</strong></td>
<td>1.14 ± 0.49</td>
<td>1.00 ± 0.46</td>
<td>1.00 ± 0.49</td>
<td>0.117</td>
<td>1.04 ± 0.49bd</td>
<td>0.87 ± 0.24c</td>
<td>0.001</td>
</tr>
<tr>
<td><strong>LAMP2 ratio</strong></td>
<td>1.13 ± 0.48</td>
<td>1.00 ± 0.45</td>
<td>0.99 ± 0.51</td>
<td>0.095</td>
<td>1.07 ± 0.52cde</td>
<td>0.73 ± 0.30c</td>
<td>0.001</td>
</tr>
<tr>
<td><strong>Ubiquitin</strong></td>
<td>1.14 ± 0.47</td>
<td>1.00 ± 0.34c</td>
<td>0.94 ± 0.35b</td>
<td>0.001</td>
<td>1.09 ± 0.51</td>
<td>0.89 ± 0.20c</td>
<td>0.033</td>
</tr>
<tr>
<td><strong>α-Synuclein (pg/mL)</strong></td>
<td>584 ± 169</td>
<td>623 ± 31ld</td>
<td>549 ± 269</td>
<td>0.309</td>
<td>518 ± 289d</td>
<td>457 ± 281c</td>
<td>0.060</td>
</tr>
<tr>
<td><strong>Abeta42 (pg/mL)</strong></td>
<td>850 ± 289</td>
<td>678 ± 255c</td>
<td>704 ± 253b</td>
<td>0.003</td>
<td>494 ± 256c</td>
<td>607 ± 212b</td>
<td>≤0.001</td>
</tr>
<tr>
<td><strong>Total-tau (pg/mL)</strong></td>
<td>207 ± 103</td>
<td>240 ± 125</td>
<td>241 ± 141</td>
<td>0.463</td>
<td>362 ± 231</td>
<td>229 ± 122</td>
<td>0.067</td>
</tr>
<tr>
<td><strong>Phospho-tau (pg/mL)</strong></td>
<td>42 ± 17</td>
<td>42 ± 17</td>
<td>40 ± 15</td>
<td>0.221</td>
<td>51 ± 27</td>
<td>38 ± 18e</td>
<td>0.089</td>
</tr>
<tr>
<td><strong>AD-positive profile, n (%)</strong></td>
<td>1 (3)</td>
<td>21 (7)</td>
<td>4 (5)</td>
<td>0.647</td>
<td>11 (22)c</td>
<td>1 (6)</td>
<td>0.033</td>
</tr>
</tbody>
</table>

Data are presented as mean ± standard deviation. Statistical analysis was done by ANCOVA with sex, age, and disease duration (if appropriate) as covariates.

*P < 0.05 compared with controls;
**P < 0.01 compared with controls;
***P < 0.001 compared with controls;
****P < 0.05 compared with GBA.

Stratification according to GBA variant severity revealed no significant differences between the PD groups (Table S1).

Within the group of DLB patients, DLBGABA_mild_severe (0.42) had lower CSF levels of LAMP2 than DLBGABA_low risk (0.91) and DLBGABA_wildtype (1.04); P < 0.05 (Supplemental Table S2).

ROC Analysis and AUC

Five proteins consistently separated all disease groups (PDGBA_wildtype, PDGBA, DLBGABA_wildtype, DLBGABA) from healthy controls: CHGA, SCG2, VGF, NPTX1, and AP2B1 and thereby representing all 3 analyzed pathways, AUC > 0.6–0.9.

In addition to the abovementioned proteins, the lysosomal protein ubiquitin discriminated between PDGBA patients and healthy controls (AUC, 0.657), whereas the lysosomal protein LAMP2 discriminated between DLBGABA patients and healthy controls (AUC, 0.735). LAMP2 also discriminated between DLBGABA and DLBGABA_wildtype (AUC, 0.695); see Figure 1.

Adding α-synuclein as a covariable to the model did not improve the AUC of the proteins in any of the models.

Associations of CSF Proteostasis Protein Levels with CSF Levels of Total α-Synuclein

In PDGBA_wildtype, PDGBA, DLBGABA_wildtype, and DLBGABA, lower CSF levels of α-synuclein were highly
Associated with lower CSF levels of all proteins identified in the ROC analysis (AP2B1, CHGA, SCG2, VGF, NPTX1, LAMP2, and ubiquitin), \( P \leq 0.01 \) (Fig. 2).

Associations of CSF Proteostasis Protein Levels with Demographics and Clinical Scales

Male sex and higher age were weakly associated with lower CSF levels of AP2B1, CHGA, SCG2, VGF, and NPTX1 \( (P < 0.05) \). Higher H&Y staging and lower MoCA were associated very weakly with lower CSF levels of SCG2, VGF, and NPTX1 \( (P < 0.05) \). LEDD was not associated with any of the proteins.

PD Patients with a Pathological CSF Protein Profile Related to \( \alpha \)-Synuclein Proteostasis Versus Those with a Normal Profile

To discriminate between PD patients with a pathologically low CSF proteostasis profile (PDpathological_proteostasis_profile) from those patients with a profile similar to healthy controls (PDnormal_proteostasis_profile), Youden’s Index was calculated for each CSF protein related to \( \alpha \)-synuclein proteostasis (Table S3). We detected 101 PD patients with a pathological CSF protein level below the cutoff in all 6 proteins, whereas 284 showed a normal profile. PDpathological_proteostasis_profile patients were younger in mean age (62 vs 67 years; \( P \leq 0.001 \)) and in mean age at onset (56 vs 60 years; \( P \leq 0.001 \)) compared with PDnormal_proteostasis_profile patients. Also, they were more often male (78% vs 62%; \( P = 0.002 \)), had higher mean H&Y scores (2.2 vs 2.1; \( P = 0.012 \)), and lower mean CSF level of total \( \alpha \)-synuclein (380 vs. 690 pg/mL; \( P \leq 0.001 \)). Mean UPDRS-III, MoCA, and BDI-II scores were not significantly different between PDpathological_proteostasis_profile and PDnormal_proteostasis_profile (Table 2).

Longitudinal Analysis in PD Patients with a Pathological CSF Protein Profile Related to \( \alpha \)-Synuclein Proteostasis Versus Those with a Normal Profile

Linear mixed-model analysis revealed that CSF levels of total \( \alpha \)-synuclein were influenced by the fixed factor group (PDpathological_proteostasis_profile vs. PDnormal_proteostasis_profile) but not by the factor time and the interaction group/time. The predicted mean was 397 pg/mL in PDpathological_proteostasis_profile vs. 662 pg/mL in PDnormal_proteostasis_profile; \( P \leq 0.001 \).

H&Y stage and MoCA score were influenced by the factor time. For both groups the yearly increase in H&Y was 0.05 points and the yearly decrease in MoCA score was 0.2 points. No effects of group, time, or group/time interaction were seen for UPDRS-III and BDI-II.

Discussion

By assessing CSF protein levels representative for major pathways associated with \( \alpha \)-synuclein proteostasis, we show: (1) Proteins associated with
neurotransmitter secretion (CHGA, SCG2, VGF), synaptic plasticity (NPTX1), and endolysosomal autophagy (AP2B1, GM2A, LAMP2, ubiquitin) were lower in PD patients and/or DLB patients compared with healthy controls. (2) These patterns were more pronounced in DLB than in PD and were accentuated by GBA variant status in both entities, PD and DLB. (3) In all analyzed cohorts, CSF levels of these proteostasis-related proteins were positively associated with CSF levels of total α-synuclein, meaning that lower levels of these proteins were associated with lower levels of total α-synuclein. (4) These findings could be confirmed longitudinally. PD patients with low CSF profiles of proteins related to proteostasis showed lower CSF levels of α-synuclein longitudinally compared with PD patients with a normal proteostasis profile. (5) Lower CSF levels of these proteostasis-related proteins were associated with lower MoCA scores and with higher H&Y staging linking biochemical profiles with clinical outcome parameters.

Decreased CSF levels of the same proteins associated with neurotransmitter secretion (CHGA, SCG2, VGF) as found in our study have recently been identified in an unbiased quantitative proteomics approach in PD patients compared with controls. Results were consistent across 3 US cohorts, one of them longitudinally. These proteins play an essential role in the regulated secretory pathway, which controls the delivery of neurotransmitters and biologically active peptides. They are co-stored in dense-core vesicles and regulate levels of catecholamines such as dopamine. Secretoneurin, a SCG2-derived peptide stimulates the release of dopamine from nigrostriatal neurons.14,15

A small study reported CSF levels of CHGA to be reduced in drug-naive PD patients compared with healthy controls. As we did not find an association between LEDD and CSF level of CHGA, these findings suggest that this pattern is already present at diagnosis and not driven by dopaminergic treatment.16 Interestingly, postmortem findings show that CHGA accumulates in cortical Lewy bodies in a developmental stage-related manner.17,18

Using an unbiased proteomics approach in 2 cohorts of patients with DLB, it was recently shown that CSF levels of SCG2 and VGF are also decreased in DLB compared with age-matched control participants. We can confirm this finding. As VGF is associated with learning and memory, the same group investigated CSF levels of VGF not only in DLB but also in AD. They found lower CSF levels of VGF in patients with DLB. FIG. 2. Correlations of CSF level of pathway-associated proteins with CSF level of total α-synuclein. [Color figure can be viewed at wileyonlinelibrary.com]
compared with either AD patients or controls. Although CSF levels of VGF were positively associated with CSF levels of α-synuclein, no association was found with CSF levels of Abeta1-42. In DLB patients, lower levels of VGF were related to more advanced cognitive impairment.\(^\text{20}\) VGF is a secreted neuronal precursor protein, and its expression is induced by brain-derived neurotrophic factor, a protein that has been repeatedly shown to be decreased in α-synucleinopathies and has been linked to dopaminergic neuronal survival.\(^\text{21}\) VGF is processed into several bioactive peptides that are implicated in energy homeostasis, synaptic bio-identification, and synaptic plastici ty.\(^\text{14}\)

Impaired synapse plasticity is emerging as an important early event in the development of α-synucleinopathies and found already in the period of brain development, as shown in a LRRK2 p.G2019S mouse model.\(^\text{22}\) Neuronal pentraxin-1 (NPTX1) belongs to a family of proteins that are involved in synaptic plasticity. Using whole-genome expression profiling, it was shown that NPTX2 is colocalized with α-synuclein aggregates in the substantia nigra and cerebral cortex in PD.\(^\text{23}\) Decreased CSF levels of NPTX1 and NPTX2 have also been shown in patients with frontotemporal dementia and even in presymptomatic mutation carriers (GRN, C9orf72, or MAPT).\(^\text{24}\)

With the identification of variants in the GBA gene as major genetic risk factor for PD and DLB, it became clear that impairment in lysosomal-mediated autophagy represents a key event in the pathogenesis of α-synucleinopathies.\(^\text{25,26}\) We think that the ROC-based differentiation between DLB\(_{\text{GBA}}\) and DLB\(_{\text{wildtype}}\) by CSF LAMP2 protein profiles further supports the importance of lysosomal dysfunction based on GBA mutations. We now seem to make progress in the field of pathway-specific biofluid markers in patient cohorts.

This was further underpinned by the finding that genetic variants in other genes associated with lysosomal storage disorders also increase the risk of developing PD.\(^\text{27}\) A recent study also found AP2B1, GM2A, and LAMP1 and LAMP2 to be decreased in PD compared with prodromal AD, AD, and healthy controls.\(^\text{3}\)

Importantly, lower CSF levels of these proteostasis-related proteins (neurotransmitter secretion, synaptic plasticity, and endolysosomal autophagy) were associated with lower CSF levels of total α-synuclein cross-sectionally and longitudinally. Previous analyses in PD and DLB demonstrated CSF levels of total α-synuclein to be decreased in both diseases compared with healthy controls with even more pronounced decrease in patients with GBA variants.\(^\text{28-31}\) This mechanistic link between proteostasis-associated proteins and α-synuclein as pathologic hallmark was previously shown in postmortem studies and cell models\(^\text{32-37}\) but seems now also detectable in vivo in patient-derived CSF. It is of importance that results and hypothesis coming from cell and animal models can be translated into patient-derived biofluid-marker studies. This field is just beginning to emerge, and we often failed to translate findings/hypothesis into patient cohort. One might imagine that composite profiles of several biofluid markers that are representative of different pathways upstream or downstream of α-synuclein might help to stratify patients for future pathway-specific trials. Of note, the pattern of reduced CSF protein profiles was more pronounced in DLB than in PD and accentuated by GBA variant status in both entities. This highlights the currently widely discussed pathomechanistic continuum between PD and DLB\(^\text{38}\) with additional acceleration because of GBA variants. It will be interesting to evaluate these protein profiles in patients with biallelic variants in recessively inherited PD genes such

---

**Table 2** Demographics and clinical variables in PD patients stratified by proteostasis profile

<table>
<thead>
<tr>
<th>Demographic/Variable</th>
<th>PD(_{\text{normal proteostasis profile, n = 284}})</th>
<th>PD(_{\text{pathological proteostasis profile, n = 101}})</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male), n (%)</td>
<td>175 (62)</td>
<td>79 (78)</td>
<td>0.002</td>
</tr>
<tr>
<td>Age (years)</td>
<td>67 ± 9</td>
<td>62 ± 10</td>
<td>≤ 0.001</td>
</tr>
<tr>
<td>Age at onset (years)</td>
<td>60 ± 10</td>
<td>56 ± 10</td>
<td>≤ 0.001</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>7 ± 5</td>
<td>6 ± 5</td>
<td>0.231</td>
</tr>
<tr>
<td>Hoehn &amp; Yahr</td>
<td>2.1 ± 0.7</td>
<td>2.2 ± 0.6</td>
<td>0.012*</td>
</tr>
<tr>
<td>UPDRS-III</td>
<td>26 ± 12</td>
<td>27 ± 11</td>
<td>0.453*</td>
</tr>
<tr>
<td>MoCA</td>
<td>25 ± 5</td>
<td>25 ± 4</td>
<td>0.338*</td>
</tr>
<tr>
<td>BDI-II</td>
<td>9 ± 7</td>
<td>9 ± 6</td>
<td>0.969*</td>
</tr>
<tr>
<td>α-Synuclein (pg/mL)</td>
<td>690 ± 300</td>
<td>380 ± 158</td>
<td>≤ 0.001*</td>
</tr>
<tr>
<td>Prevalence GBA mutation, n (%)</td>
<td>55 (19%)</td>
<td>25 (25%)</td>
<td>0.256</td>
</tr>
</tbody>
</table>

Data are presented as mean ± standard deviation. Statistical analysis was done by ANOVA.

*ANCOVA with sex and age as covariables.
as parkin and PINK1, as these patients often show nigral degeneration without the typical α-synuclein aggregation.

The association of these proteostasis-related proteins with main clinical outcomes such as disease staging by H&Y and cognitive function measured by MoCA warrants further investigation. It will be valuable to assess these proteins in prospective longitudinal cohorts in which CSF along with more complex clinical data and longitudinal clinical trajectories is available from de novo PD patients with several years of follow-up. Such analysis will help to evaluate whether these proteins might serve as biological progression markers that relate to clinical outcomes.

Strengths of our study are: (1) the large monocentric standardized collection of high-quality CSF samples minimizing variance in sample collection and processing; and (2) the validation of findings in longitudinal PD samples and in another α-synucleinopathy, namely, DLB, which represents a histopathological continuum with even more pronounced features.

The study had these limitations. (1) As our cohort comprised early- to mid-stage patients, we cannot conclude whether findings are causation or consequence. Therefore, we suggest to explore these findings in de novo and, ideally, prodromal cohorts. (2) The investigated proteins may not be fully representative of the involved pathways that have been discussed. (3) The number of healthy controls is smaller than the number of PD and DLB patients. (4) We lack a direct validation in brain samples from the same patients from whom these CSF profiles were assessed. (5) It is technically possible to measure at least some of the pathway-specific proteins in blood samples, which would be less invasive. However, we do not know whether blood levels of these proteins reflect the CNS milieu. Therefore, it would be important to analyze CSF/blood pairs in future studies to answer this question.

Taken together, our findings suggest that proteins associated with neurotransmitter secretion, synaptic plasticity, and endolysosomal autophagy might serve as biomarkers related to α-synuclein proteostasis in PD and DLB.

Data Availability Statement

Anonymized data are available upon request (kathrin.brockmann@uni-tuebingen.de)

References


Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.
Author Roles

S.L.: Conception, design of the study; execution of the statistical analysis, writing of the first draft
A.B.: Acquisition of study data, critical review of the manuscript
K.B.: Acquisition of study data, critical review of the manuscript
I.W.: Acquisition of study data, critical review of the manuscript
B.R.: Acquisition of study data, critical review of the manuscript
M.Z.: Acquisition of study data, critical review of the manuscript
A.-K.H.: Acquisition of study data, critical review of the manuscript
I.L.-S.: Acquisition of study data, critical review of the manuscript
K.B.: Conception, organization and execution of the study, manuscript preparation, critical review of the manuscript

Financial Disclosures

Stefanie Lerche, Isabel Wurster, Benjamin Roeben, Milan Zimmermann Ann-Kathrin Hauser, Simon Sjödin, and Ann Brinkmalm have nothing to disclose.

Inga Liepelt-Scarfone reports the following grants: International Parkinson Funds (Deutschland) GmbH (IPD), Janssen - Pharmaceutical Companies of Johnson & Johnson, European Commission, H2020-TWINN-2015, National Center of Excellence in Research, Luxembourg National Research Fund, and the Michael J Fox Foundation.

Katharina Waniek and Ingolf Lachmann are employees at Roboscreen.

Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. He has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).

Kai Blennow is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), and European Union Joint Program for Neurodegenerative Disorders (JPN2019-466-236). He has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.

Thomas Gasser serves as associate editor at Journal of Parkinson's disease; holds a patent re: KASPP (LRRK2) Gene, its Production and Use for the Detection and Treatment of Neurodegenerative Diseases; serves as a consultant for Cephalon, Inc. and Merck Serono; serves on speaker's bureaus of Novartis, Merck Serono, SCHWARZ PHARMA, Boehringer Ingelheim, and Valeant Pharmaceuticals International; and receives research support from Novartis, the European Union, BMBF (the Federal Ministry of Education and Research), and Helmholtz Association.
Kathrin Brockmann has received a research grant from the German Society of Parkinson’s disease (dpv); funding from the Michael J. Fox Foundation (MJFF) and the German Centre for Neurodegenerative Diseases (DZNE, MIGAP); travel grants from the Movement Disorders Society and speaker honoraria from Abbvie, Lundbeck, UCB and Zambon.